Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Clinical Research

Pathologic T stage and tumor volume predicted by PCA3 mRNA levels in urine of prostate cancer patients before radical prostatectomy

Eric Whitman, Jack Groskopf, Amina Ali, Yongmei Chen, Amy Blase, Bungo Furusato, Gyorgy Petrovics, Mona Ibrahim, Sally Elsamanoudi, Jennifer Cullen, Isabell Sesterhenn, Stephen Brassell, Harry Rittenhouse, Shiv Srivastava and David McLeod
Eric Whitman
Walter Reed Army Medical Center, Washington, DC, Gen-Probe, Inc, San Diego, CA, Center for Prostate Disease Research, Rockville, MD, Armed Forces Institute of Pathology, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jack Groskopf
Walter Reed Army Medical Center, Washington, DC, Gen-Probe, Inc, San Diego, CA, Center for Prostate Disease Research, Rockville, MD, Armed Forces Institute of Pathology, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amina Ali
Walter Reed Army Medical Center, Washington, DC, Gen-Probe, Inc, San Diego, CA, Center for Prostate Disease Research, Rockville, MD, Armed Forces Institute of Pathology, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yongmei Chen
Walter Reed Army Medical Center, Washington, DC, Gen-Probe, Inc, San Diego, CA, Center for Prostate Disease Research, Rockville, MD, Armed Forces Institute of Pathology, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amy Blase
Walter Reed Army Medical Center, Washington, DC, Gen-Probe, Inc, San Diego, CA, Center for Prostate Disease Research, Rockville, MD, Armed Forces Institute of Pathology, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bungo Furusato
Walter Reed Army Medical Center, Washington, DC, Gen-Probe, Inc, San Diego, CA, Center for Prostate Disease Research, Rockville, MD, Armed Forces Institute of Pathology, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gyorgy Petrovics
Walter Reed Army Medical Center, Washington, DC, Gen-Probe, Inc, San Diego, CA, Center for Prostate Disease Research, Rockville, MD, Armed Forces Institute of Pathology, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mona Ibrahim
Walter Reed Army Medical Center, Washington, DC, Gen-Probe, Inc, San Diego, CA, Center for Prostate Disease Research, Rockville, MD, Armed Forces Institute of Pathology, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sally Elsamanoudi
Walter Reed Army Medical Center, Washington, DC, Gen-Probe, Inc, San Diego, CA, Center for Prostate Disease Research, Rockville, MD, Armed Forces Institute of Pathology, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Cullen
Walter Reed Army Medical Center, Washington, DC, Gen-Probe, Inc, San Diego, CA, Center for Prostate Disease Research, Rockville, MD, Armed Forces Institute of Pathology, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabell Sesterhenn
Walter Reed Army Medical Center, Washington, DC, Gen-Probe, Inc, San Diego, CA, Center for Prostate Disease Research, Rockville, MD, Armed Forces Institute of Pathology, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Brassell
Walter Reed Army Medical Center, Washington, DC, Gen-Probe, Inc, San Diego, CA, Center for Prostate Disease Research, Rockville, MD, Armed Forces Institute of Pathology, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harry Rittenhouse
Walter Reed Army Medical Center, Washington, DC, Gen-Probe, Inc, San Diego, CA, Center for Prostate Disease Research, Rockville, MD, Armed Forces Institute of Pathology, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shiv Srivastava
Walter Reed Army Medical Center, Washington, DC, Gen-Probe, Inc, San Diego, CA, Center for Prostate Disease Research, Rockville, MD, Armed Forces Institute of Pathology, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David McLeod
Walter Reed Army Medical Center, Washington, DC, Gen-Probe, Inc, San Diego, CA, Center for Prostate Disease Research, Rockville, MD, Armed Forces Institute of Pathology, Washington, DC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2008
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

Abstract

LB-216

Background and Objective: Clinicians have been searching for more accurate prognostic information to guide their patients in choosing treatment for prostate cancer. PCA3 is a prostate specific non-protein coding gene that is over expressed in a majority of prostate cancers. Recent studies have reported diagnostic, as well as prognostic potential of PCA3 mRNA levels in post-digital rectal examination (DRE) urine. This study was conducted to assess the relationship between PCA3 mRNA levels in the post-DRE urine and subsequent clinico-pathologic features of tumors in whole mount specimens.
Patients and Methods: Post-DRE urine specimens were obtained from 65 men with prostate cancer before undergoing radical prostatectomy as their primary treatment. PCA3 and PSA mRNA levels were then measured in the whole urine using assays developed by Gen-Probe, Inc, San Diego, CA. PCA3 levels were normalized to PSA mRNA in each sample and the ratio was recorded as a PCA3 score. This score was then correlated with the comprehensive pathologic data from whole-mounted prostate specimens analyzed at the Armed Forces Institute of Pathology and compared with various other clinico-pathologic features.
Results: Patients with pT3 disease had much higher PCA3 score (median = 48.8, range =7.5-269.0) than pT2 patients (median = 18.7, range = 4.0-79.9), p = 0.02. Spearman analysis showed that PCA3 score significantly correlated with total tumor volume (n = 72, R = 0.38, P < .01). Patients with larger tumor volume (>2.0 cc) have significantly (p = 0.01) higher PCA3 score (median = 47.6, range = 7.5 - 269.0) compared to patients with smaller tumor volume (0.5 - 2.0 cc: median=17.5; <0.5 cc: median=18.7). Adjusted by other pre-surgical variables (age, race, serum PSA, clinical stage, biopsy grade, etc.), stepwise multivariate logistic regression analyses showed that PCA3 score was an independent predictor of pT3 prostate cancer (p = 0.01) and for a total tumor volume of <0.5 cc (p = 0.04). This is the first report of a urine assay predicting pathologic stage in prostate cancer.
Conclusions: This study shows that measurement of PCA3 score in the post-DRE urine of prostate cancer patients has potential to provide valuable prognostic information. Future studies addressing prognostic value of this assay are underway.

Footnotes

  • 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

  • American Association for Cancer Research
Previous
Back to top
Cancer Research: 68 (9 Supplement)
May 2008
Volume 68, Issue 9 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pathologic T stage and tumor volume predicted by PCA3 mRNA levels in urine of prostate cancer patients before radical prostatectomy
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Pathologic T stage and tumor volume predicted by PCA3 mRNA levels in urine of prostate cancer patients before radical prostatectomy
Eric Whitman, Jack Groskopf, Amina Ali, Yongmei Chen, Amy Blase, Bungo Furusato, Gyorgy Petrovics, Mona Ibrahim, Sally Elsamanoudi, Jennifer Cullen, Isabell Sesterhenn, Stephen Brassell, Harry Rittenhouse, Shiv Srivastava and David McLeod
Cancer Res May 1 2008 (68) (9 Supplement) LB-216;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Pathologic T stage and tumor volume predicted by PCA3 mRNA levels in urine of prostate cancer patients before radical prostatectomy
Eric Whitman, Jack Groskopf, Amina Ali, Yongmei Chen, Amy Blase, Bungo Furusato, Gyorgy Petrovics, Mona Ibrahim, Sally Elsamanoudi, Jennifer Cullen, Isabell Sesterhenn, Stephen Brassell, Harry Rittenhouse, Shiv Srivastava and David McLeod
Cancer Res May 1 2008 (68) (9 Supplement) LB-216;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Clinical Research

  • Abstract NG15: Investigation of relationships between breast cancer risk factors and bilateral mammographic breast density asymmetry among women undergoing diagnostic image-guided breast biopsies
  • Abstract LB-139: Efficacy, safety, and changes in blood markers following sunitinib monotherapy in patients with advanced hepatocellular carcinoma: Experience from a multidisciplinary Phase II study
  • Abstract LB-141: The Adenoma Prevention with Celecoxib (APC) trial: Five-year efficacy and safety results
Show more Clinical Research

Biomarkers : Poster Presentations - Late-Breaking Abstracts

  • Colon Cancer Secreted Protein 2 (CCSP-2) is a potential biomarker for colorectal cancer.
  • Cytokine and angiogenic factor (CAF) profiling for prediction of outcome to first line sorafenib (SR) versus SR plus low-dose interferon-α (IFNα) in patients with advanced renal cell carcinoma (mRCC)
  • Predictors of AZD6244 (ARRY-142886) response are cell line dependent
Show more Biomarkers : Poster Presentations - Late-Breaking Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement